Dietary curcumin counteracts extracellular transthyretin deposition: Insights on the mechanism of amyloid inhibition

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 1, 2013, Pages 39-45

  Ferreira, Nelson ^a   Santos, Sónia A O ^b   Domingues, Maria Rosário M ^c   Saraiva, Maria João ^a,d   Almeida, Maria Rosário ^a,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF AVEIRO   (Portugal)

^c UNIVERSITY OF AVEIRO   (Portugal)

^d UNIVERSITY OF PORTO   (Portugal)

Author keywords

Amyloid; Curcumin; Familial amyloidotic polyneuropathy; Transthyretin

Indexed keywords

3 NITROTYROSINE; AMYLOID; CURCUMIN; FAS ANTIGEN; GLUCOSE REGULATED PROTEIN 78; PREALBUMIN; TETRAMER; THYROXINE;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; CONTROLLED STUDY; CYTOTOXICITY TEST; DIETARY INTAKE; DISSOCIATION; DRUG BINDING; DRUG SELECTIVITY; ENDOPLASMIC RETICULUM; FAMILIAL AMYLOID POLYNEUROPATHY; ISOELECTRIC FOCUSING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; TRANSTHYRETIN AMYLOIDOSES;

AMYLOID; AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; CURCUMIN; HUMANS; MICE; MICE, TRANSGENIC; PREALBUMIN;

CURCUMA LONGA; MUS;

EID: 84868592337     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.10.007     Document Type: Article

References (41)

1. Westermark P. Aspects on human amyloid forms and their fibril polypeptides. FEBS J. 2005, 5942-5949.
2. Pepys M.B. Amyloidosis. Annu. Rev. Med. 2006, 57:223-241.
3. Ando Y., Nakamura M., Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch. Neurol. 2005, 62:1057-1062.
4. Rapezzi C., Quarta C.C., Riva L., Longhi S., Gallelli I., Lorenzini M., Ciliberti P., Biagini E., Salvi F., Branzi A. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat. Rev. Cardiol. 2010, 7:398-408.
5. Saraiva M.J., Birken S., Costa P.P., Goodman D.S. Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J. Clin. Invest. 1984, 74:104-119.
6. Quintas A., Saraiva M.J., Brito R.M. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Lett. 1997, 418:297-300.
7. Johnson S.M., Wiseman R.L., Sekijima Y., Green N.S., Adamski-Werner S.L., Kelly J.W. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidosis. Acc. Chem. Res. 2005, 38:911-921.
8. Altland K., Winter P. Potential treatment of transthyretin-type amyloidoses by sulfite. Neurogenetics 1999, 2:183-188.
9. Miroy G.J., Lai Z., Lashuel H.A., Peterson S.A., Strang C., Kelly J.W. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:15051-15056.
10. Ferreira N., Saraiva M.J., Almeida M.R. Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Lett. 2011, 585:2424-2430.
11. Kohno K., Palha J.A., Miyakawa K., Saraiva M.J., Ito S., Mabuchi T., Blaner W.S., Iijima H., Tsukahara S., Episkopou V., Gottesman M.E., Shimada K., Takahashi K., Yamamura K., Maeda S. Analysis of amyloid deposition in a transgenic mouse model of homozygous familial amyloidotic polyneuropathy. Am. J. Pathol. 1997, 150:1497-1508.
12. Almeida M.R., Macedo B., Cardoso I., Alves I., Valencia G., Arsequell G., Planas A., Saraiva M.J. Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochem. J. 2004, 381:351-356.
13. Singh S.V., Hu X., Srivastava S.K., Singh M., Xia H., Orchard J.L., Zaren H.A. Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. Carcinogenesis 1998, 19:1357-1360.
14. Iqbal M., Sharma S.D., Okazaki Y., Fujisawa M., Okada S. Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. Pharmacol. Toxicol. 2003, 92:33-38.
15. Murphy E.A., Davis J.M., McClellan J.L., Gordon B.T., Carmichael M.D. Curcumin's effect on intestinal inflammation and tumorigenesis in the ApcMin/+ mouse. J. Interferon Cytokine Res. 2011, 31:219-226.
16. Lee J.C., Kinniry P.A., Arguiri E., Serota M., Kanterakis S., Chatterjee S., Solomides C.C., Javvadi P., Koumenis C., Cengel K.A., Christofidou-Solomidou M. Dietary curcumin increases antioxidant defenses in lung, ameliorates radiation-induced pulmonary fibrosis, and improves survival in mice. Radiat. Res. 2010, 173:590-601.
17. Sousa M.M., Cardoso I., Fernandes R., Guimaraes A., Saraiva M.J. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy, evidence for toxicity of nonfibrillar aggregates. Am. J. Pathol. 2001, 159:1993-2000.
18. Teixeira P.F., Cerca F., Santos S.D., Saraiva M.J. Endoplasmic reticulum stress associated with extracellular aggregates. Evidence from transthyretin deposition in familial amyloid polyneuropathy. J. Biol. Chem. 2006, 281:21998-22003.
19. Macedo B., Batista A.R., Ferreira N., Almeida M.R., Saraiva M.J. Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochim. Biophys. Acta 2008, 1782:517-522.
20. Ono K., Hasegawa K., Naiki H., Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 2004, 75:742-750.
21. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., Cole G.M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. 2005, 280:5892-5901.
22. Garcia-Alloza M., Borrelli L.A., Rozkalne A., Hyman B.T., Bacskai B.J. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem. 2007, 102:1095-1104.
23. Hickey M.A., Zhu C., Medvedeva V., Lerner R.P., Patassini S., Franich N.R., Maiti P., Frautschy S.A., Zeitlin S., Levine M.S., Chesselet M.F. Improvement of neuropathology and transcriptional deficits in CAG 140 knock-in mice supports a beneficial effect of dietary curcumin in Huntington's disease. Mol. Neurodegener. 2012, 7:12.
24. Pullakhandam R., Srinivas P.N., Nair M.K., Reddy G.B. Binding and stabilization of transthyretin by curcumin. Arch. Biochem. Biophys. 2009, 485:115-119.
25. Goel A., Kunnumakkara A.B., Aggarwal B.B. Curcumin as "Curecumin": from kitchen to clinic. Biochem. Pharmacol. 2008, 75:787-809.
26. Perkins S., Verschoyle R.D., Hill K., Parveen I., Threadgill M.D., Sharma R.A., Williams M.L., Steward W.P., Gescher A.J. Chemopreventive efficacy and pharmacokinetics of curcumin in the min/+ mouse, a model of familial adenomatous polyposis. Cancer Epidemiol. Biomarkers Prev. 2002, 11:535-540.
27. Saraiva M.J., Magalhaes J., Ferreira N., Almeida M.R. Transthyretin deposition in familial amyloidotic polyneuropathy. Curr. Med. Chem. 2012, 19:2304-2311.
28. Guo J.T., Yu J., Grass D., de Beer F.C., Kindy M.S. Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J. Neurosci. 2002, 22:5900-5909.
29. Macedo B., Magalhães J., Batista A.R., Saraiva M.J. Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model. Pharmacol. Res. 2010, 62:514-522.
30. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 2001, 21:8370-8377.
31. Begum A.N., Jones M.R., Lim G.P., Morihara T., Kim P., Heath D.D., Rock C.L., Pruitt M.A., Yang F., Hudspeth B., Hu S., Faull K.F., Teter B., Cole G.M., Frautschy S.A. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J. Pharmacol. Exp. Ther. 2008, 326:196-208.
32. Fiala M., Liu P.T., Espinosa-Jeffrey A., Rosenthal M.J., Bernard G., Ringman J.M., Sayre J., Zhang L., Zaghi J., Dejbakhsh S., Chiang B., Hui J., Mahanian M., Baghaee A., Hong P., Cashman J. Innate immunity and transcription of MGAT-III and Toll-like receptors in Alzheimer's disease patients are improved by bisdemethoxycurcumin. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:12849-12854.
33. Gagliardi S., Ghirmai S., Abel K.J., Lanier M., Gardai S.J., Lee C., Cashman J.R. Evaluation in vitro of synthetic curcumins as agents promoting monocytic gene expression related to β-amyloid clearance. Chem. Res. Toxicol. 2012, 25:101-112.
34. Purkey H.E., Dorrell M.I., Kelly J.W. Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc. Natl. Acad. Sci. 2001, 98:566-5571.
35. Coelho T., Maia L.F., Martins da Silva A., Waddington Cruz M., Planté-Bordeneuve V., Lozeron P., Suhr O.B., Campistol J.M., Conceição I.M., Schmidt H.H., Trigo P., Kelly J.W., Labaudinière R., Chan J., Packman J., Wilson A., Grogan D.R. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012, 79:785-792.
36. Ferreira N., Cardoso I., Domingues M.R., Vitorino R., Bastos M., Bai G., Saraiva M.J., Almeida M.R. Binding of epigallocatechin-3-gallate to transthyretin modulates its amyloidogenicity. FEBS Lett. 2009, 583:3569-3576.
37. Ferreira N., Saraiva M.J., Almeida M.R. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models. PLoS One 2012, 7:e29933.
38. Miyata M., Sato T., Kugimiya M., Sho M., Nakamura T., Ikemizu S., Chirifu M., Mizuguchi M., Nabeshima Y., Suwa Y., Morioka H., Arimori T., Suico M.A., Shuto T., Sako Y., Momohara M., Koga T., Morino-Koga S., Yamagata Y., Kai H. The crystal structure of the green tea polyphenol (-)-epigallocatechin gallate-transthyretin complex reveals a novel binding site distinct from the thyroxine binding site. Biochemistry 2010, 49:6104-6114.
39. Kristen A.V., Lehrke S., Buss S., Mereles D., Steen H., Ehlermann P., Hardt S., Giannitsis E., Schreiner R., Haberkorn U., Schnabel P.A., Linke R.P., Röcken C., Wanker E.E., Dengler T.J., Altland K., Katus H.A. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin. Res. Cardiol. 2012, 101:805-813.
40. Burgos-Morón E., Calderón-Montaño J.M., Salvador J., Robles A., López-Lázaro M. The dark side of curcumin. Int. J. Cancer 2010, 126:1771-1775.
41. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: problems and promises. Mol. Pharm. 2007, 4:807-818.